Navigation Links
PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Date:8/20/2007

Novel cardioprotective agent to move forward in Phase III development

NEW YORK, Aug. 20 /PRNewswire/ -- PeriCor Therapeutics announced today that its licensing agreement for acadesine with Schering-Plough Corporation has become effective. The agreement grants Schering-Plough exclusive worldwide rights for the development and commercialization of PeriCor's lead compound, acadesine. Financial terms of the transaction were not disclosed.

Acadesine is currently under evaluation in Phase III clinical development as an intravenous infusion for the prevention of adverse cardiovascular and cerebrovascular outcomes that occur as complications associated with ischemia-reperfusion injury in patients undergoing coronary artery bypass graft (CABG) surgery. Acadesine has been studied in placebo-controlled trials that enrolled more than 4,000 patients. Schering-Plough will conduct an additional randomized, placebo-controlled Phase III trial needed for regulatory approval. An agent, such as acadesine, that can be shown to reduce the surgical complications of stroke, heart failure and death that can accompany CABG would not only make an important contribution to patients' well-being, but would also be anticipated to reduce health care costs dramatically.

"Schering-Plough possesses the vital organizational and financial resources to complete the clinical and regulatory processes required to make this life-saving medicine available to cardiac surgeons and anesthesiologists around the world," said Richard R. Stover, President and Chief Executive Officer of PeriCor Therapeutics. Commenting further, Mr. Stover said, "We are especially impressed with the caliber of Schering-Plough's cardiovascular group in clinical development, medical, and marketing activities and their unparalleled record of innovation in this therapeutic area."

Previous clinical experience with acadesine in placebo-controlled studies in CABG surgery suggests that acadesine may have unique
'/>"/>

SOURCE PeriCor Therapeutics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , ... August 27, 2015 , ... Inc. Magazine released ... ranking iLab Solutions as number 1,361 in growth for the three years through 2014. ... top 0.1% fastest-growing privately held organizations in the country. , “We are thrilled ...
(Date:8/26/2015)... , ... August 26, 2015 , ... ... announces today that a second US laboratory is to open in Manhattan, Kansas ... the continued partnership and long-term growth of research and development through collaboration with ...
(Date:8/26/2015)... Aug. 26, 2015  The Diabetes Research Institute ... of Miami Miller School of Medicine, announced today ... to test for the first time a novel ... This FDA approved Phase I/II study builds upon ... is an important first step toward the development ...
(Date:8/26/2015)... 26, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... wholly owned by Mr. Yuen Kam, chairman of the ... outstanding shares (the "Shares") of  Excellent China Healthcare Investment ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... JERICHO, N.Y., March 13, 2012   Health Care ... Via Christi Health System of Wichita, Kansas has ... rate just two months after selecting and implementing ... COI disclosure process. (Logo: http://photos.prnewswire.com/prnh/20061010/NYTU194LOGO ...
... Allentown, Pa., March 13, 2012  Good Shepherd Rehabilitation ... in the rehabilitation of physical and cognitive disabilities, ... the United States. Ekso (formerly called eLEGS) is ... www.eksobionics.com ) that allows those with lower-extremity paralysis ...
... Pharma IQ has just published the results of ... management specialist with nearly half of those questioned having a ... samples. According to the survey results, 66.7 per ... as primary concerns in their current role or department: the ...
Cached Biology Technology:Conflict of Interest Management System Selected by Via Christi Health 2Conflict of Interest Management System Selected by Via Christi Health 3Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton 2Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton 3Pharma IQ's Compound Management Survey Report 2
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... at Dana-Farber Cancer Institute and the Broad Institute of MIT ... genes that may serve as an Achilles, heel for many ... issue of the journal Cell , the researchers identified ... been identified as potential targets for cancer therapy. Unlike most ...
... A University of Toronto (U of T) team led by Engineering ... garnered third place and $40,000 (USD) for their design of a ... to the Bill & Melinda Gates Foundation,s Reinvent the Toilet Challenge, ... and affordable for people in the developing world that doesn,t have ...
... Uzuntarla from Bulent Ecevit University, Turkey, and his colleagues ... which is present in the nervous system. The article ... work has implications for explaining how noise, modulated by ... of neurons to external stimuli as part of the ...
Cached Biology News:'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 2'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 3University of Toronto wins third place at the Gates Foundation's Reinvent the Toilet Challenge 2
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... Get better net results - with a ... and data management! The ChemStation Plus NDS ... control, data acquisition and data management, giving ... that meets your labs needs now and ...
... Solubility Service, We deliversoluble protein or ... technology yields the best soluble protein results ... each clone submitted , Powerful results on ... protein Solubility Optimization Service (SOS) uses proprietary ...
... The Schleicher & Schuell BioScience Arraying ... dedicated to custom protein and nucleic ... project teams, comprised of R&D, Engineering, ... closely with collaborators every step of ...
Biology Products: